About Nevro
Nevro is a company based in Menlo Park (United States) founded in 2006 was acquired by Globus Medical in February 2025. Nevro has raised $154.1 million across 8 funding rounds from investors including Medtronic, Globus Medical and CRG. The company has 1,215 employees as of December 31, 2023. Nevro has completed 1 acquisition, including VYRSA Technologies. Nevro operates in a competitive market with competitors including Vertos Medical, Spineart, Paradigm Spine, ATEC Spine and Relievant Medsystems, among others.
- Headquarter Menlo Park, United States
- Employees 1215 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nevro Corp
-
Annual Revenue
$353.08 M (USD)502as on Mar 31, 2024
-
Net Profit
-$113.44 M (USD)-23as on Mar 31, 2024
-
EBITDA
-$126.23 M (USD)-27as on Mar 31, 2024
-
Total Equity Funding
$154.1 M (USD)
in 8 rounds
-
Latest Funding Round
$189.75 M (USD), Post-IPO
Apr 10, 2020
-
Investors
Medtronic
& 11 more
-
Employee Count
1215
as on Dec 31, 2023
- Investments & Acquisitions
-
Acquired by
Globus Medical
(Feb 06, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Nevro
Unlock access to complete
Unlock access to complete
Software Development Team
159 people
Leadership Team
66 people
Sales and Marketing
61 people
Product Management Team
41 people
Spine Team
21 people
Senior Team
15 people
Legal and Compliance
9 people
Operations Team
7 people
Unlock access to complete
Funding Insights of Nevro
Nevro has successfully raised a total of $154.1M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $189.75 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $189.8M
-
First Round
First Round
(04 Dec 2006)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Post-IPO - Nevro | Valuation |
investors |
|
| Jun, 2016 | Amount | Post-IPO - Nevro | Valuation |
investors |
|
| Dec, 2014 | Amount | Debt – Conventional - Nevro | Valuation |
investors |
Investors in Nevro
Nevro has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Medtronic, Globus Medical and CRG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Early-stage US healthcare investments are made by Accuitive Medical Ventures.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nevro
Nevro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include VYRSA Technologies.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Sacroiliac joint fusion technologies are specialized in by VYRSA Technologies.
|
2021 |
Financial Statements - Nevro
Nevro Comparisons
Competitors of Nevro
Nevro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vertos Medical, Spineart, Paradigm Spine, ATEC Spine and Relievant Medsystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Minimally invasive treatments for lumbar spinal stenosis are developed.
|
|
| domain | founded_year | HQ Location |
Developer of orthopedic implants and minimally invasive instruments
|
|
| domain | founded_year | HQ Location |
Stabilization devices for healthcare are manufactured by the company.
|
|
| domain | founded_year | HQ Location |
Treatment solutions for spine disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of medical devices for patients suffering from chronic vertebrogenic low back pain
|
Frequently Asked Questions about Nevro
Nevro was founded in 2006.
Nevro is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Nevro is a funded company, having raised a total of $154.1M across 8 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $20M, raised on Dec 04, 2006.
As of Dec 31, 2023, the latest employee count at Nevro is 1,215.
Annual revenue of Nevro is $353.08M as on Mar 31, 2024.
Nevro was founded in 2006 and is based in Menlo Park, United States. The company operates within the medical device sector, specializing in neuromodulation for pain management. Spinal cord stimulation therapies are delivered via the Senza SCS system, which employs high-frequency technology. Development and distribution of these implants occur primarily in the U.S., targeting chronic pain conditions.
Nevro's top competitors include Paradigm Spine, ATEC Spine and Vertos Medical.
Nevro has made 1 acquisition, including VYRSA Technologies.
Nevro has 12 investors. Key investors include Medtronic, Globus Medical, CRG, NEA, and Accuitive Medical Ventures.